Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 26Unknown 3Recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 208Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 113Myelodysplastic Syndromes 96Leukemia 82Lymphoma 65Lymphoma, Non-Hodgkin 57Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37Leukemia, Myelomonocytic, Chronic 35Neoplasms 31Recurrence 27Myeloproliferative Disorders 27Burkitt Lymphoma 25Lymphoma, Mantle-Cell 23Leukemia, Biphenotypic, Acute 23Lymphoma, Large B-Cell, Diffuse 22Lymphoma, Follicular 20Lymphoma, B-Cell, Marginal Zone 20Lymphoma, B-Cell 20Leukemia, Myeloid, Chronic-Phase 16Leukemia, B-Cell 16Hodgkin Disease 16Primary Myelofibrosis 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Waldenstrom Macroglobulinemia 14Hematologic Diseases 14Anemia, Refractory, with Excess of Blasts 11Neoplasm, Residual 9

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Philadelphia Chromosome × Other hematologic neoplasm × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡